Hemophilus Influenzae Type B Vaccine

G. Haroche; T. Lang; D. Rea; Ch Lafaix; Dan M. Granoff; Michael T. Osterholm; Trudy V. Murphy

doi:10.1056/NEJM198501033120117

Hemophilus Influenzae Type B Vaccine

G. Haroche, T. Lang, D. Rea, Ch Lafaix, Dan M. Granoff, Michael T. Osterholm, Trudy V. Murphy

Center for Infectious Disease Research and Policy

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

To the Editor: We were very interested in the article by Peltola and colleagues reporting the effectiveness of immunization with a capsular polysaccharide Hemophilus influenzae type b (Hib) vaccine in preventing H. influenzae bacteremic infections in Finland (June 14 issue).¹ As suggested by the authors, their recommendation that the Hib vaccine be given to all children at the age of 18 months may not necessarily be applicable in developing countries. We are conducting a study of the Hib vaccine, particularly its adjuvant effect, in children under 18 months of age in the Republic of Upper Volta (West Africa). In a.

Original language	English (US)
Pages (from-to)	53-54
Number of pages	2
Journal	New England Journal of Medicine
Volume	312
Issue number	1
DOIs	https://doi.org/10.1056/NEJM198501033120117
State	Published - Jan 3 1985

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1056/NEJM198501033120117

Find It

Find It at U of M Libraries

Cite this

@article{72ef3a64cf2f4b45b7e8da7fba163d9f,

title = "Hemophilus Influenzae Type B Vaccine",

abstract = "To the Editor: We were very interested in the article by Peltola and colleagues reporting the effectiveness of immunization with a capsular polysaccharide Hemophilus influenzae type b (Hib) vaccine in preventing H. influenzae bacteremic infections in Finland (June 14 issue).1 As suggested by the authors, their recommendation that the Hib vaccine be given to all children at the age of 18 months may not necessarily be applicable in developing countries. We are conducting a study of the Hib vaccine, particularly its adjuvant effect, in children under 18 months of age in the Republic of Upper Volta (West Africa). In a.",

author = "G. Haroche and T. Lang and D. Rea and Ch Lafaix and Granoff, {Dan M.} and Osterholm, {Michael T.} and Murphy, {Trudy V.}",

year = "1985",

month = jan,

day = "3",

doi = "10.1056/NEJM198501033120117",

language = "English (US)",

volume = "312",

pages = "53--54",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "1",

}

TY - JOUR

T1 - Hemophilus Influenzae Type B Vaccine

AU - Haroche, G.

AU - Lang, T.

AU - Rea, D.

AU - Lafaix, Ch

AU - Granoff, Dan M.

AU - Osterholm, Michael T.

AU - Murphy, Trudy V.

PY - 1985/1/3

Y1 - 1985/1/3

N2 - To the Editor: We were very interested in the article by Peltola and colleagues reporting the effectiveness of immunization with a capsular polysaccharide Hemophilus influenzae type b (Hib) vaccine in preventing H. influenzae bacteremic infections in Finland (June 14 issue).1 As suggested by the authors, their recommendation that the Hib vaccine be given to all children at the age of 18 months may not necessarily be applicable in developing countries. We are conducting a study of the Hib vaccine, particularly its adjuvant effect, in children under 18 months of age in the Republic of Upper Volta (West Africa). In a.

AB - To the Editor: We were very interested in the article by Peltola and colleagues reporting the effectiveness of immunization with a capsular polysaccharide Hemophilus influenzae type b (Hib) vaccine in preventing H. influenzae bacteremic infections in Finland (June 14 issue).1 As suggested by the authors, their recommendation that the Hib vaccine be given to all children at the age of 18 months may not necessarily be applicable in developing countries. We are conducting a study of the Hib vaccine, particularly its adjuvant effect, in children under 18 months of age in the Republic of Upper Volta (West Africa). In a.

UR - http://www.scopus.com/inward/record.url?scp=0021967549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021967549&partnerID=8YFLogxK

U2 - 10.1056/NEJM198501033120117

DO - 10.1056/NEJM198501033120117

M3 - Letter

C2 - 3871123

AN - SCOPUS:0021967549

VL - 312

SP - 53

EP - 54

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 1

ER -

Hemophilus Influenzae Type B Vaccine

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this